Valuation: Arvinas, Inc.

Market Cap 572M 495M 462M 424M 797M 54.45B 810M 5.42B 2.13B 27.29B 2.15B 2.1B 90.23B P/E 2026 *
180x
P/E 2027 * -2.54x
Enterprise Value 127M 110M 103M 94.06M 177M 12.08B 180M 1.2B 472M 6.06B 477M 466M 20.02B EV / Sales 2026 *
0.42x
EV / Sales 2027 * 3.99x
Free-Float
79.97%
Yield 2026 *
-
Yield 2027 * -
1 day+0.81%
1 week+8.97%
Current month+8.97%
1 month+2.22%
3 months-13.45%
6 months-35.09%
Current year-26.22%
1 week 7.92
Extreme 7.92
9.65
1 month 7.9
Extreme 7.895
9.65
Current year 6.97
Extreme 6.97
14.51
1 year 6.32
Extreme 6.32
14.51
3 years 5.9
Extreme 5.9
53.08
5 years 5.9
Extreme 5.9
98.67
10 years 5.9
Extreme 5.9
108.46
Manager TitleAgeSince
Chief Executive Officer 47 11/02/2026
Director of Finance/CFO 56 23/06/2024
Chief Tech/Sci/R&D Officer 58 16/06/2024
Director TitleAgeSince
Chairman 66 14/06/2023
Director/Board Member 64 30/06/2018
Chairman 67 11/02/2026
Date Insider Type Main position Quantity % Market Cap.
06/03/26 Buy

Chairman

20,000 0.0313%
27/02/26 Sell

Director

35,297 0.0550%
26/02/26 Free

Controller/Auditor

30,924 0.0482%
Change 5-day change 1-year change 3-year change Capi.($)
+0.81%+8.97%+39.11%-63.99% 572M
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +3.54%+11.41%+52.51%+180.46% 26.41B
Weighted average by Cap. +4.35%+13.09%+50.67%+167.97%

Financials

2026 *2027 *
Net sales 299M 259M 242M 222M 417M 28.5B 424M 2.84B 1.11B 14.28B 1.12B 1.1B 47.23B 66.63M 57.63M 53.82M 49.37M 92.87M 6.34B 94.34M 631M 248M 3.18B 250M 245M 10.51B
Net income 1.5M 1.3M 1.21M 1.11M 2.09M 143M 2.12M 14.22M 5.58M 71.57M 5.63M 5.51M 237M -250M -216M -202M -185M -349M -23.8B -354M -2.37B -930M -11.93B -939M -919M -39.44B
Net Debt -445M -385M -360M -330M -620M -42.37B -630M -4.22B -1.66B -21.24B -1.67B -1.64B -70.21B -306M -265M -247M -227M -427M -29.13B -433M -2.9B -1.14B -14.6B -1.15B -1.12B -48.27B
Logo Arvinas, Inc.
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Employees
246
Date Price Change Volume
07/08/26 US$8.750 +0.81% 1,218,176
06/08/26 US$8.680 +3.33% 2,580,578
05/08/26 US$8.400 -6.67% 1,571,545
04/08/26 US$9.000 +11.66% 3,032,794
03/08/26 US$8.060 +0.37% 716,844
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
8.750USD
Average target price
14.00USD
Spread / Average Target
+60.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARVN Stock